Compare AADX & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AADX | LIVN |
|---|---|---|
| Founded | N/A | 1987 |
| Country | | United Kingdom |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.5B |
| IPO Year | 2026 | 2015 |
| Metric | AADX | LIVN |
|---|---|---|
| Price | $18.01 | $78.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $72.43 |
| AVG Volume (30 Days) | ★ 972.7K | 622.0K |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.79 |
| Revenue Next Year | N/A | $6.63 |
| P/E Ratio | ★ N/A | $196.53 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.57 | $41.02 |
| 52 Week High | $24.24 | $85.27 |
| Indicator | AADX | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 43.69 |
| Support Level | $16.93 | $61.63 |
| Resistance Level | $24.24 | $80.96 |
| Average True Range (ATR) | 1.63 | 2.31 |
| MACD | -0.32 | -0.78 |
| Stochastic Oscillator | 14.22 | 27.67 |
Applied Aerospace & Defense Inc specializes in providing engineering and vertically integrated manufacturing solutions for space and defense technology companies. The company builds complex hardware for extreme operating environments, combining deep material science and IP-enabled process expertise with the ability to enable rapid prototyping, enhance new product development, and responsively scale production. The majority of the company's revenue is derived from the sales of Defense Aviation and Airborne Systems, followed by Space and Launch Systems, C5ISR and Precision Strike Systems.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.